Struma ovarii screening

Revision as of 14:08, 16 October 2017 by Aravind Reddy Kothagadi (talk | contribs) (Undo revision 1374568 by Mmir (talk))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Struma ovarii Microchapters


Patient Information


Historical Perspective




Differentiating Struma ovarii from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Struma ovarii screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Struma ovarii screening

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Struma ovarii screening

CDC on Struma ovarii screening

Struma ovarii screening in the news

Blogs on Struma ovarii screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Struma ovarii screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]


There is insufficient evidence to recommend routine screening for Struma ovarii. However, in cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease.



  1. Volpi E, Ferrero A, Nasi PG, Sismondi P (2003). "Malignant struma ovarii: a case report of laparoscopic management". Gynecol. Oncol. 90 (1): 191–4. PMID 12821363.
  2. Zekri JM, Manifold IH, Wadsley JC (2006). "Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments". Clin Oncol (R Coll Radiol). 18 (10): 768–72. PMID 17168212.
  3. Sinha NK (2014). "Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary". J Clin Diagn Res. 8 (3): 140–1. doi:10.7860/JCDR/2014/8005.4138. PMC 4003614. PMID 24783110.
  4. Balci TA, Kabasakal L (2005). "Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?". Gynecol. Oncol. 99 (2): 520. doi:10.1016/j.ygyno.2005.04.017. PMID 15963556.
  5. McGill JF, Sturgeon C, Angelos P (2009). "Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation". Endocr Pract. 15 (2): 167–73. doi:10.4158/EP.15.2.167. PMID 19289330.

Template:WH Template:WS